S C Efe1, K Demirci2, S Ozturk3, A S Gurbuz4, N Poci5, A Kilicgedik6, A Guler6, M F Yilmaz6, I A İzgi6, C Kirma6. 1. Department of Cardiology, Agrı State Hospital, Fırat mahallesi, 00004, Agrı, Turkey. scaganefe@gmail.com. 2. Department of Cardiology, Goztepe Research and Education Hospital, Istanbul, Turkey. 3. Department of Cardiology, Haseki Training and Education Hospital, Istanbul, Turkey. 4. Department of Cardiology, Eskisehir State Hospital, Eskisehir, Turkey. 5. Department of Cardiology, Herz-Zentrum Bodensee Konstanz, Konstanz, Germany. 6. Department of Cardiology, Kosuyolu Kartal Heart Training and Research Hospital, Istanbul, Turkey.
Abstract
BACKGROUND: Endocan is a recently introduced marker of endothelial dysfunction and is also associated with inflammation and atherosclerosis. To date, the relationship between cardiac syndrome X (CSX) and endocan has not been studied. The objective of this study was to compare the serum endocan levels of patients with CSX with those of control subjects. PATIENTS AND METHODS: In this study, 50 patients were included in the CSX group and 28 patients in the control group. Patients with pathological conditions that could potentially influence endothelial functions were excluded. Endocan serum concentrations were measured using an enzyme-linked immunosorbent assay. RESULTS: The mean endocan level of the CSX group was significantly higher than that of the control group (3051.3 ± 1900.5 ng/l vs. 2088.1 ± 522.2 ng/l; p = 0.002). There was no difference between the two groups in terms of age, gender, hypertension, diabetes mellitus, dyslipidemia, and smoking status. In receiver operating characteristic (ROC) curve analysis, endocan levels greater than 2072 ng/l had a 72% sensitivity and 54% specificity (p = 0.002) for accurately predicting a diagnosis of CSX. CONCLUSION: The results of this study suggest that patients with CSX have higher endocan levels. Therefore, endocan may be valuable in helping uncover the underlying pathogenesis of CSX.
BACKGROUND:Endocan is a recently introduced marker of endothelial dysfunction and is also associated with inflammation and atherosclerosis. To date, the relationship between cardiac syndrome X (CSX) and endocan has not been studied. The objective of this study was to compare the serum endocan levels of patients with CSX with those of control subjects. PATIENTS AND METHODS: In this study, 50 patients were included in the CSX group and 28 patients in the control group. Patients with pathological conditions that could potentially influence endothelial functions were excluded. Endocan serum concentrations were measured using an enzyme-linked immunosorbent assay. RESULTS: The mean endocan level of the CSX group was significantly higher than that of the control group (3051.3 ± 1900.5 ng/l vs. 2088.1 ± 522.2 ng/l; p = 0.002). There was no difference between the two groups in terms of age, gender, hypertension, diabetes mellitus, dyslipidemia, and smoking status. In receiver operating characteristic (ROC) curve analysis, endocan levels greater than 2072 ng/l had a 72% sensitivity and 54% specificity (p = 0.002) for accurately predicting a diagnosis of CSX. CONCLUSION: The results of this study suggest that patients with CSX have higher endocan levels. Therefore, endocan may be valuable in helping uncover the underlying pathogenesis of CSX.
Authors: Raquel del Toro; Claudia Prahst; Thomas Mathivet; Geraldine Siegfried; Joshua S Kaminker; Bruno Larrivee; Christiane Breant; Antonio Duarte; Nobuyuki Takakura; Akiyoshi Fukamizu; Josef Penninger; Anne Eichmann Journal: Blood Date: 2010-08-12 Impact factor: 22.113
Authors: Eyüp Büyükkaya; Mehmet Fatih Karakaş; Mustafa Kurt; Sedat Motor; Adnan Burak Akçay; Sule Büyükkaya; Esra Karakaş; Nihat Sen Journal: Turk Kardiyol Dern Ars Date: 2013-06
Authors: Hanan Hassan Sabry; Jehan Hassan Sabry; Aliaa El Husseiny Daifalla; Essam Mohamed Akl; Ahmed Mohamed Hamed; Ahmed Abd Allah Torky Journal: Vasc Health Risk Manag Date: 2018-07-09